DeepMed Research

Orexigen Therapeutics, Inc

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study to Evaluate the Effect of Naltrexone and Bupropion Combination on the Pharmacokinetics of Metformin in Healthy Participants

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Naltrexone/Bupropion
Drug: Metformin

First Posted Date: 2016-04-20

Last Posted Date: 2016-09-29

Lead Sponsor: Orexigen Therapeutics, Inc

Target Recruit Count: 30

Registration Number: NCT02745912

Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants

Phase 1

Completed

Conditions: Heart Repolarization

Interventions: Drug: Naltrexone HCl/bupropion HCl
Other: Placebo
Drug: Moxifloxacin

First Posted Date: 2016-04-12

Last Posted Date: 2016-11-01

Lead Sponsor: Orexigen Therapeutics, Inc

Target Recruit Count: 84

Registration Number: NCT02735603

Naltrexone/Bupropion Cardiovascular Outcomes Study

Phase 4

Terminated

Conditions: Obesity
Cardiovascular Diseases

Interventions: Drug: Naltrexone HCl/Bupropion HCl ER
Drug: Placebo

First Posted Date: 2015-12-22

Last Posted Date: 2017-02-27

Lead Sponsor: Orexigen Therapeutics, Inc

Target Recruit Count: 67

Registration Number: NCT02638129

Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)
Drug: Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)

First Posted Date: 2014-10-08

Last Posted Date: 2014-12-11

Lead Sponsor: Orexigen Therapeutics, Inc

Target Recruit Count: 80

Registration Number: NCT02259179

Locations: 🇺🇸
Quintiles Phase One Services, LLC, Overland Park, Kansas, United States

Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects

Phase 3

Completed

Conditions: Obesity
Overweight

Interventions: Drug: NB
Behavioral: Usual Care
Behavioral: CLI

First Posted Date: 2013-01-09

Last Posted Date: 2015-12-29

Lead Sponsor: Orexigen Therapeutics, Inc

Target Recruit Count: 242

Registration Number: NCT01764386

Locations: 🇺🇸
Radiant Research-Akron, Akron, Ohio, United States
🇺🇸
PMG Research of Winston-Salem, Hickory, North Carolina, United States
🇺🇸
PMG Research of Salisbury, Salisbury, North Carolina, United States

and more 9 locations

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

Phase 3

Terminated

Conditions: Obesity
Overweight

Interventions: Drug: NB32
Drug: PBO
Behavioral: Weight Management Program

First Posted Date: 2012-05-18

Last Posted Date: 2017-02-27

Lead Sponsor: Orexigen Therapeutics, Inc

Target Recruit Count: 8910

Registration Number: NCT01601704

Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder

Phase 2

Terminated

Conditions: Obsessive-Compulsive Disorder

Interventions: Drug: Naltrexone SR 32 mg
Drug: Naltrexone 32 mg and fluoxetine 60 mg
Drug: Fluoxetine 60 mg

First Posted Date: 2008-09-25

Last Posted Date: 2012-11-29

Lead Sponsor: Orexigen Therapeutics, Inc

Target Recruit Count: 8

Registration Number: NCT00758966

Locations: 🇺🇸
Northbrooke Research Center, Brown Deer, Wisconsin, United States
🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States

and more 8 locations

Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects

Phase 2

Terminated

Conditions: Schizophrenia
Schizoaffective Disorder
Schizophreniform Disorder

Interventions: Drug: zonisamide SR plus olanzapine
Drug: Placebo plus olanzapine

First Posted Date: 2008-08-14

Last Posted Date: 2012-11-29

Lead Sponsor: Orexigen Therapeutics, Inc

Target Recruit Count: 26

Registration Number: NCT00734435

Locations: 🇺🇸
Florida Clinical Research Center, Maitland, Florida, United States
🇺🇸
UCI Medical Center, Orange, California, United States
🇺🇸
Synergy Research, National City, California, United States

and more 6 locations

A Study Using Functional Magnetic Resonance Imaging (fMRI) to Assess the Effects of Naltrexone SR/ Bupropion SR Therapy in Overweight or Obese Subjects

Phase 2

Completed

Conditions: Obesity

Interventions: Drug: Placebo
Drug: Naltrexone SR 32 mg/bupropion SR 360 mg/day
Other: fMRI scan

First Posted Date: 2008-07-09

Last Posted Date: 2015-01-06

Lead Sponsor: Orexigen Therapeutics, Inc

Target Recruit Count: 46

Registration Number: NCT00711477

Locations: 🇺🇸
Brookhaven National Laboratory Medical Department, Upton, New York, United States

Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity

Phase 2

Completed

Conditions: Obesity

Interventions: Drug: Zonisamide SR placebo/ bupropion SR placebo
Drug: Zonisamide SR 120 mg/day/ bupropion SR placebo
Drug: Zonisamide SR 360 mg/day/ bupropion SR placebo
Drug: Zonisamide SR placebo/ bupropion SR 360 mg/day
Drug: Zonisamide SR 120 mg/day/ bupropion SR 360 mg/day
Drug: Zonisamide SR 360 mg/day/ bupropion SR 360 mg/day

First Posted Date: 2008-07-03

Last Posted Date: 2012-11-29

Lead Sponsor: Orexigen Therapeutics, Inc

Target Recruit Count: 729

Registration Number: NCT00709371

Locations: 🇺🇸
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
🇺🇸
Welborn Clinic, Evansville, Indiana, United States
🇺🇸
Miami Research Associates, Miami, Florida, United States

and more 17 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy